Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Microbial Differences in Prostate Lesions Between Black and White American Men.

The Prostate·2026
Same author

Strategies for Aortic Root Measurement in Patients Undergoing Surveillance for Thoracic Aortic Disease.

Journal of clinical medicine·2026
Same author

Clinical, Physiologic, and Anatomic Outcomes of a Novel Bioprosthetic Aortic Valved Conduit.

Journal of clinical medicine·2026
Same author

Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Reprogramming the immune microenvironment in triple-negative breast cancer with mRNA therapeutics.

Cancer letters·2026

Related Experiment Video

Updated: Sep 16, 2025

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.6K

miRNAs Regulating GSTP1 as Potential Diagnostic Biomarkers in Prostate Cancer.

Shiv Verma1,2, Cheryl L Thompson3, Pingfu Fu4

  • 1Department of Urology, Case Western Reserve University, Cleveland, Ohio, USA.

The Prostate
|July 10, 2025
PubMed
Summary

New microRNAs (miRNAs) show promise as blood-based biomarkers for early prostate cancer detection. A panel of two specific miRNAs, hsa-miR-133a-3p and hsa-miR-153-3p, demonstrated high accuracy, outperforming PSA tests.

Keywords:
T‐cell receptorblood‐based biomarkerscancer diagnosisglutathione S‐transferase P1microRNAprostate cancer

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.6K

Related Experiment Videos

Last Updated: Sep 16, 2025

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.6K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Prostate cancer early detection requires sensitive and specific minimally-invasive biomarkers.
  • MicroRNAs (miRNAs) are emerging as promising blood-based biomarkers due to their dysregulation in cancer.

Purpose of the Study:

  • To identify specific and sensitive microRNA (miRNA) biomarkers for early prostate cancer detection.
  • To evaluate the diagnostic accuracy of identified miRNAs compared to Prostate-Specific Antigen (PSA) levels.

Main Methods:

  • Quantitative real-time PCR was used to measure miRNA levels in plasma from 44 prostate cancer patients and 42 controls.
  • Receiver Operating Characteristic (ROC) curve analysis evaluated the sensitivity and specificity of candidate miRNAs.
  • ELISA assay detected serum PSA and plasma GSTP1 levels.

Main Results:

  • Target prediction identified hsa-miR-133a-3p, hsa-miR-144-3p, hsa-miR-153-3p, and hsa-miR-590 as potential biomarkers regulating GSTP1.
  • hsa-miR-133a-3p and hsa-miR-153-3p showed exceptional specificity and sensitivity for prostate cancer detection (p < 0.0001 and p = 0.0003, respectively).
  • A two-miRNA panel achieved high diagnostic accuracy (AUC 0.98-1.0), outperforming PSA levels.

Conclusions:

  • A two-miRNA panel (hsa-miR-133a-3p and hsa-miR-153-3p) shows significant potential as a reliable blood-based diagnostic tool for prostate cancer.
  • This miRNA panel represents a substantial advancement over current PSA testing for prostate cancer detection.